Clinical Trial Search

Phase 3 N=431 A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)

Plaque Type Psorisis

Primary: Percentage (%) of Patients Who Reach Psoriasis Area Severity Index (PASI) 90 at 16 Weeks - LOCF Approach (ITT Set) — 80.4; 81.7 percentage of participants

Novartis Pharmaceuticals Results Apr 2019 7.2% serious AE View details

Phase 3 N=387 A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

Primary: The Percentage of Participants With Drug-Related Grade 3 - 5 Adverse Events (AEs) — 32.8; 45.5 Percentage of participants — p=0.0144

Bristol-Myers Squibb Results Apr 2019 64.9% serious AE View details

Phase 3 N=129 Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

Subjects With Hyperlipidemia, Dyslipidemia

Primary: Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16 — -5.31; -8.31 percent change — p=0.18

Amgen Results Apr 2019 1.6% serious AE View details

Phase 3 N=698 Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee · Osteoarthritis, Hip

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16 — -2.64; -3.23; -3.37 units on a scale — p=0.0129

Pfizer Results Apr 2019 3.9% serious AE View details

Phase 3 N=151 Prevention of Post-operative Urinary Retention

Urinary Retention · Urinary Tract Infections

Primary: Need for Any Intermittent Catheterization Postoperatively as a Binary Outcome — 18; 22 Participants

University of Wisconsin, Madison Results Apr 2019 5.3% serious AE View details

Phase 3 N=24 Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

PCOS

Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml

University of California, San Diego Results Apr 2019 0.0% serious AE View details

Phase 3 N=30 A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

Epilepsy

Primary: Number of Participants With Treatment Emergent (TE) Serious Adverse Events (SAEs) and Non-SAEs — 23; 5 Participants

GlaxoSmithKline Results Apr 2019 14.7% serious AE View details

Phase 3 N=722 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Infection, Human Immunodeficiency Virus · HIV Infections

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48 — 93; 94 Percentage of…

ViiV Healthcare Results Apr 2019 9.8% serious AE View details

Phase 3 N=480 Phase 3 Trial of Serbian Seasonal Influenza Vaccine

Influenza

Primary: Number of Participants With Solicited Adverse Events (Local & Systemic Reactogenicity) — 5; 1; 5; 0 Participants

Institute of Virology, Vaccines and Sera, Torlak Results Apr 2019 0.4% serious AE View details

Phase 3 N=222 A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

Parkinson's Disease

Primary: Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 185; 39 Participants

Takeda Results Apr 2019 17.6% serious AE View details

Phase 3 N=227 A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Treatment-resistant Depression

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using…

Janssen Research & Development, LLC Results Apr 2019 1.0% serious AE View details

Phase 3 N=458 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

Alopecia, Androgenetic

Primary: Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24 — 20.2; 6.7; 21.1 Hairs — p=<.001

Polichem S.A. Results Apr 2019 2.2% serious AE View details

Phase 3 N=719 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Infection, Human Immunodeficiency Virus · HIV Infections

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48 — 90; 93 Percentage of…

ViiV Healthcare Results Apr 2019 8.5% serious AE View details

Phase 3 N=295 Steroids In Eosinophil Negative Asthma

Asthma

Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…

Milton S. Hershey Medical Center Results Apr 2019 1.0% serious AE View details

Phase 3 N=346 A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Treatment-resistant Depression

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated…

Janssen Research & Development, LLC Results Apr 2019 1.4% serious AE View details